<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="980">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486508</url>
  </required_header>
  <id_info>
    <org_study_id>99060</org_study_id>
    <nct_id>NCT04486508</nct_id>
  </id_info>
  <brief_title>Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19</brief_title>
  <acronym>INSPIRATION</acronym>
  <official_title>Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajaie Cardiovascular Medical and Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tehran Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masih Daneshvari Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hazrat Rasool Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Modarres Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Firuzgar hospital affiliated to Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imam Khomeini Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sina Hospital, Iran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rajaie Cardiovascular Medical and Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a 2x2 factorial design randomized controlled trial, the investigators aim to elaborate the
      safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients
      with COVID-19. The first randomization entails open-label assignment to intermediate versus
      standard dose prophylactic anticoagulation. The investigators hypothesize that intermediate
      dose compared with standard prophylactic dose anticoagulation will have a superior efficacy
      with respect to a composite of venous thromboembolism (VTE), requirement for extracorporeal
      membrane oxygenation (ECMO), or all-cause mortality. The second randomization will be
      double-blind assignment of the included patients to atorvastatin 20mg daily versus matching
      placebo. The hypothesis is that statin therapy, compared with placebo, will reduce the
      composite of VTE, need for ECMO, or all-cause mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease-2019 (COVID-19) -- a viral illness caused by the severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) -- has important manifestations outside the pulmonary
      parenchyma, including microthrombosis and macrothrombosis, with venous thrombosis being the
      most common form of thrombotic involvement. Existing studies, depending on the type of
      outcome assessment and type and dose of prophylaxis, have reported thrombotic events in 7-85%
      of patients with COVID-19.

      However, the optimal antithrombotic regimen in these patients remains uncertain. Although
      many clinicians continue to consider standard-dose prophylactic anticoagulation, other
      believe that more intense anticoagulation may reduce the thrombotic events, and improve
      outcomes. However, limited high-quality data exist to inform clinical practice and the
      existing guidelines recommendations are mostly based on expert opinion and consensus.

      In addition, exuberant inflammatory response is known to play a role in the pathophysiology
      of acute respiratory distress syndrome (ARDS) and COVID-19. It is possible that the
      pleiotropic effects of statins, which include anti-inflammatory and antithrombotic effects,
      prove beneficial in patients with severe COVID-19.

      This study plans to investigate the safety and efficacy of two pharmacological regimens on
      outcomes of critically-ill patients with COVID-19 using a 2x2 factorial design.

      First, patients will be assessed for the eligibility criteria for the anticoagulation
      hypothesis. Those meeting the criteria, will be assigned to intermediate versus standard dose
      prophylactic anticoagulation. These patients will subsequently be assessed for eligibility
      for the second randomization, and if meeting the criteria, will be assigned to atorvastatin
      20mg/d or matching placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">December 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>1:1 multicenter open-label 2x2 factorial design randomized controlled trial with allocation sequence concealment and blinded endpoint adjudication.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>For the first hypothesis, allocation sequence concealment and blinded endpoint adjudication.
For the second hypothesis, allocation sequence concealment, double-blind medication administration, and blinded endpoint adjudication.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of incident VTE, undergoing ECMO, and all-cause mortality</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>Composite of objectively-confirmed venous thromboembolism, undergoing extracorporeal membrane oxygenation (ECMO), or death from any cause</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Intermediate dose anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose anticoagulation will be the the tested regimen. The anticoagulation regimen will be modified according to weight/ body mass index, and creatinine clearance level (Cl Cr). Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according to Cockcroft-Gault Formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard prophylaxis dose anticoagulation will be the anticoagulation of choice in the control arm. Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according Cockcroft-Gault Formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 20 mg daily will be the statin therapy of choice in the intervention arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be used for the control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intermediate dose Enoxaparin/ unfractionated heparin</intervention_name>
    <description>Intermediate dose anticoagulation according to creatinine clearance and weight</description>
    <arm_group_label>Intermediate dose anticoagulation</arm_group_label>
    <other_name>Intermediate dose anticoagulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard prophylactic dose Enoxaparin/ unfractionated heparin</intervention_name>
    <description>Standard prophylaxis anticoagulation according to creatinine clearance and weight</description>
    <arm_group_label>Standard Prophylaxis</arm_group_label>
    <other_name>Standard dose prophylaxis anticoagulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>Statin</description>
    <arm_group_label>Atorvastatin 20</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <description>Matched placebo to atorvastatin 20 mg</description>
    <arm_group_label>Atorvastatin 20 mg Matched placebo</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Anticoagulation Hypothesis

          1. Adult patients (≥18 years), with polymerase chain reaction (PCR)-confirmed COVID-19
             admitted to ICU within 7 days of initial hospitalization , who do not have another
             firm indication for anticoagulation (such as mechanical valve, high-risk atrial
             fibrillation (AF), VTE, or left ventricle (LV) thrombus),who are not enrolled in
             another blinded randomized trial, and are willing to participate in the study and
             provide informed consent .

          2. Estimated survival of at least 24 hours at the discretion of enrolling physician

        Exclusion Criteria for Anticoagulation Hypothesis

          1. Weight &lt;40 Kilogram (kg)

          2. Overt bleeding at the day of enrollment

          3. Known major bleeding within 30 days (according to the Bleeding Academic Research
             Consortium (BARC) definition, Appendix A)

          4. Platelet count &lt;50,000/Fl

          5. Pregnancy (as confirmed by Beta human chorionic gonadotropin (HCG) testing among
             female patients &lt;50 years)

          6. Patients on Extracorporeal Membrane Oxygenation (ECMO)

          7. History of heparin induced thrombocytopenia or immune thrombocytopenia

          8. Ischemic stroke within the past 2 weeks

          9. Craniotomy/major neurosurgery within the past 3 months

         10. Major head or spinal trauma in the past 30 days

         11. Known brain metastases or vascular malformations (aneurysm)

         12. Presence of an epidural, spinal or pericardial catheter

         13. Major surgery other than neurosurgery within 14 days prior to enrollment

         14. Coexistence of severe obesity (weight &gt;120 kg or BMI&gt;35 kg/m2 along with severe renal
             insufficiency defined as creatinine clearance (CrCl) &lt;30 mL/sec)

         15. Allergic reaction to study medications

         16. Lack or withdrawal of informed consent

        Inclusion Criteria for the Statin Randomization

          1. Patients enrolled for the anticoagulation randomization

          2. Willingness to participation in the study and providing informed consent

        Exclusions Criteria for the Statin Randomization

          1. Baseline liver function tests&gt; 3 times upper normal limits (ULN) or creatine kinase
             (CK) &gt;500 U/L

          2. Active liver disease (LFT&gt;3 ULN plus histologic finding including cirrhosis or
             inflammation or necrosis)

          3. Routine use of statins prior to the index hospitalization

          4. Previous documented statin intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parham Sadeghipour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajaie Cardiovascular Medical and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Behnood Bikdeli, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parham Sadeghipour, MD</last_name>
    <phone>+989121454319</phone>
    <email>psadeghipour@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Tayyebi, MS</last_name>
    <phone>+989126541675</phone>
    <email>sara.tayyebi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masih Daneshvari Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>199691110</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babak Sharif Kashani</last_name>
      <phone>+989121793688</phone>
      <email>sharifkashani@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32311448/</url>
    <description>COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32473596/</url>
    <description>Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>August 2, 2020</last_update_submitted>
  <last_update_submitted_qc>August 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rajaie Cardiovascular Medical and Research Center</investigator_affiliation>
    <investigator_full_name>Parham Sadeghipour</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>statin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

